Optimizing antibiotic therapy of group IV community-acquired pneumonia patients

Journal Title: Медичні перспективи - Year 2014, Vol 19, Issue 2

Abstract

The aim of the study was to evaluate the clinical and economical effectiveness of differentiated antibacterial therapy of group IV patients with community-acquired pneumonia (CAP). Materials and methods. 42 patients, admitted to the hospital with severe CAP without risk factors for P. aeruginosa infection were randomized in three groups in 1:1:1 ratio. All patients received sequential antibacterial therapy with i.v. amoxicillin/clavulanate or ceftriaxone, or ertapenem in combination with azithromycin switched to oral amoxicillin/clavulanate, cefuroxime axetil in combination with oral azithromycin or levofloxacin, respectively, after initial improvement in 3–4 days. A comparative effectiveness analysis was performed based on clinical, laboratory and economic data. Results. Treatment outcomes in all subgroups of patients were similar: in 1st subgroup the cure rate was (28,6  12,1) %, improvement – in (49,4  13,2) % of patients; in 2nd and 3rd subgroups the cure/improvement rates were (35,7  12,8) and (42,9 13,2) %, respectively (р  0,05). Conclusion. Antibacterial therapy, always empiric and differentiated depending on severity of disease, con¬comitant conditions and previous use of antibiotics within 3 months of the onset of the disease, is a milestone of treatmet of CAP patients. A sequential antibiotic therapy with either aminopenicillin (amoxicillin/clavulanate) of 3rd generation cephalosporin (ceftriaxone/cefuroxime axetil) in combination with macrolide (azithromycin) or carbapenem (ertapenem, followed by levofloxacin) is recommended in hospitalized clinical group IV CAP patients without risk factors for P. aeruginosa infection. In current group of patients pharmacoeconomic analysis confirmed the expediency of administration a sequential antibiotic therapy with parenteral amoxicillin/clavulanat or ceftriaxone in combination with azithromycin, followed by oral amoxicillin/clavulanat or cefuroxime axetil in combination with azithromycin upon stabilization of patient’s condition. 

Authors and Affiliations

Ya. Dziublyk

Keywords

Related Articles

Analysis of the states of the activity of the laboratory service of the industrial region of Ukraine and the ways of it optimization

The purpose of the study is to analyze the activity of the laboratory service of the Dnepropetrovsk region, to develop and substantiate the concept of optimizing its work. We have carried out in dynamics the analysis of...

Иммунологические особенности парвовирусной инфекции в разные периоды беременности

Инфицирование беременных парвовирусной инфекцией сопро­вождалось развитием иммунопатологических реакций. Было обследовано 129 инфицированных беременных и 16 женщин с физиологической беременностью в I, II и III триместрах...

Professor Mykola Mykhailovych Paranko (to 85-th birthday)

Professor Mykola Mykhailovych Paranko (to 85-th birthday)

Тканинні особливості перекисного окиснення ліпідів у щурів за умов тривалого впливу оксиетильованих нонілфенолів та їх похідних 

Проведено исследование состояния процессов ПОЛ белых крыс в условиях длительного влияния оксиэтилированных нонилфенолов и их производных. Установлено, что на 45 сутки воздействия оксиэтилированные нонилфенолы в дозах 1...

Історичний нарис кафедри патологічної фізіології Дніпропетровської медичної академії

Исторический очерк кафедры патологической физиологии Днепропетровской медицинской академии. Козлова Ю.В., Довгаль М.А., Колдунов В.В., Силкина Ю.В., Клопоцкий Г.А., Худяков А.Е., Хмель С.И., Бибикова В.Н., Трясак Н.С., А...

Download PDF file
  • EP ID EP94308
  • DOI -
  • Views 107
  • Downloads 0

How To Cite

Ya. Dziublyk (2014). Optimizing antibiotic therapy of group IV community-acquired pneumonia patients. Медичні перспективи, 19(2), 32-38. https://europub.co.uk/articles/-A-94308